ROME, July 10 — Against the backdrop of a century of medical discovery, the story of Alzheimer’s disease is one of slow, painstaking progress punctuated by profound setbacks. It began in a German clinic in 1906, when psychiatrist Alois Alzheimer examined the brain of a 51-year-old patient named Auguste Deter and found abnormal clumps, now known as amyloid plaques, and tangled bundles of fibers called tau tangles. For decades after that first description, the condition was considered rare, a footnote in the annals of neurology.
The wider picture shifted dramatically in the 1970s and 1980s. Research accelerated with the identification of cholinergic deficits in the brain and the discovery that beta-amyloid was the main component of those plaques first seen by Alzheimer.
In 1992, a pivotal hypothesis emerged from scientists John Hardy and Gerald Higgins. They proposed the amyloid cascade hypothesis, which posits that the accumulation of amyloid-beta triggers a chain reaction, leading to tau pathology and, ultimately, neurodegeneration. This idea would come to dominate the field for the next three decades.
In the corridors of research institutions and pharmaceutical companies, the hunt for a treatment became a crusade. The Alzheimer’s Association was founded in 1980, giving the cause an institutional voice.
Funding from the National Institute on Aging rose sharply, from $631 million in 2015 to $3.5 billion in 2023, reflecting a growing political and public urgency. Yet the results on the clinical front have been sobering. The first major clinical trial targeting amyloid, using a drug called tramiprosate, failed in 2007.
That failure was not an anomaly. What is at stake became clear in a 2014 analysis by researcher Jeffrey Cummings. He found that of the more than 200 clinical trials conducted since 2000 for drugs targeting amyloid, the failure rate stood at 99 percent.
The numbers are stark, but they tell a story of a disease that has repeatedly defied easy solutions. The amyloid cascade hypothesis, while still influential, has faced increasing scrutiny as compound after compound failed to slow cognitive decline in patients.
The history of Alzheimer’s is thus a paradox: a century after its discovery, no disease-modifying treatment exists, yet the scientific understanding of its molecular underpinnings has never been deeper. The plaques and tangles that Alois Alzheimer first sketched in his laboratory notes remain the central puzzle. The failure of so many trials has forced a re-evaluation of the basic assumptions about the disease, with some researchers now arguing that amyloid may be a marker rather than the primary cause.
For European researchers, the story carries particular weight. The disease was first described on the continent, and many of the foundational studies in the 1970s and 1980s came from European laboratories.
The amyloid cascade hypothesis itself was proposed by scientists working in the United Kingdom. Against this backdrop, the European Union has invested heavily in biomarker research and large-scale cohort studies, hoping to identify the disease earlier, before irreversible damage is done. The wider picture, as of mid-2026, is one of cautious recalibration.
The failure of the amyloid-targeting trials has not halted research, but it has changed its direction. New avenues are being explored: tau-based therapies, inflammation modulators, and genetic approaches. The sheer scale of the challenge, however, remains daunting.
With the National Institute on Aging’s funding having increased more than fivefold over the past decade, the resources are there. The question is whether the science can catch up.
What to watch next: the results of ongoing trials targeting tau tangles and the growing interest in combination therapies. The history of Alzheimer’s research teaches that breakthroughs are rarely sudden; they are built on the rubble of failed hypotheses. The field may be poised for such a shift, but the evidence is not yet in. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Alzheimer’s Research: From 1906 Discovery to Amyloid Hypothesis”, “description”: “ROME, July 10 — Against the backdrop of a century of medical discovery, the story of Alzheimer’s disease is one of slow, painstaking progress punctuated…”, “datePublished”: “2026-07-10T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Beatrice Bianchi”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
